vs
Side-by-side financial comparison of Regional Management Corp. (RM) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $167.3M, roughly 1.8× Regional Management Corp.). Bio-Techne runs the higher net margin — 12.8% vs 6.8%, a 6.0% gap on every dollar of revenue. On growth, Regional Management Corp. posted the faster year-over-year revenue change (9.4% vs -6.4%). Over the past eight quarters, Regional Management Corp.'s revenue compounded faster (8.2% CAGR vs 4.2%).
Millennium Management LLC is an investment management firm with a multistrategy hedge fund offering. It is one of the world's largest alternative asset management firms with $83.4 billion assets under management as of January 2026. The firm operates in America, Europe and Asia. As of 2022, Millennium had posted the fourth highest net gains of any hedge fund since its inception in 1989.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
RM vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $167.3M | $295.9M |
| Net Profit | $11.4M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 6.8% | 12.8% |
| Revenue YoY | 9.4% | -6.4% |
| Net Profit YoY | 62.7% | 68.3% |
| EPS (diluted) | $1.18 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $167.3M | — | ||
| Q4 25 | $169.7M | $295.9M | ||
| Q3 25 | $165.5M | — | ||
| Q2 25 | $157.4M | $317.0M | ||
| Q1 25 | $153.0M | $316.2M | ||
| Q4 24 | $154.8M | $297.0M | ||
| Q3 24 | $146.3M | $289.5M | ||
| Q2 24 | $143.0M | $306.1M |
| Q1 26 | $11.4M | — | ||
| Q4 25 | $12.9M | $38.0M | ||
| Q3 25 | $14.4M | — | ||
| Q2 25 | $10.1M | $-17.7M | ||
| Q1 25 | $7.0M | $22.6M | ||
| Q4 24 | $9.9M | $34.9M | ||
| Q3 24 | $7.7M | $33.6M | ||
| Q2 24 | $8.4M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 9.5% | 18.4% | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | 8.6% | -7.5% | ||
| Q1 25 | 6.0% | 12.2% | ||
| Q4 24 | 8.2% | 16.0% | ||
| Q3 24 | 6.9% | 13.8% | ||
| Q2 24 | 7.8% | 15.0% |
| Q1 26 | 6.8% | — | ||
| Q4 25 | 7.6% | 12.8% | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | 6.4% | -5.6% | ||
| Q1 25 | 4.6% | 7.1% | ||
| Q4 24 | 6.4% | 11.7% | ||
| Q3 24 | 5.2% | 11.6% | ||
| Q2 24 | 5.9% | 13.3% |
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.30 | $0.24 | ||
| Q3 25 | $1.42 | — | ||
| Q2 25 | $1.03 | $-0.11 | ||
| Q1 25 | $0.70 | $0.14 | ||
| Q4 24 | $0.96 | $0.22 | ||
| Q3 24 | $0.76 | $0.21 | ||
| Q2 24 | $0.86 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $375.8M | $2.0B |
| Total Assets | $2.1B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | $260.0M | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.5B | $346.0M | ||
| Q1 25 | $1.5B | $330.0M | ||
| Q4 24 | $1.5B | $300.0M | ||
| Q3 24 | $1.4B | $300.0M | ||
| Q2 24 | $1.4B | $319.0M |
| Q1 26 | $375.8M | — | ||
| Q4 25 | $373.1M | $2.0B | ||
| Q3 25 | $371.9M | — | ||
| Q2 25 | $363.0M | $1.9B | ||
| Q1 25 | $357.9M | $2.0B | ||
| Q4 24 | $357.1M | $2.1B | ||
| Q3 24 | $352.9M | $2.1B | ||
| Q2 24 | $344.9M | $2.1B |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $2.5B | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | $2.6B | ||
| Q1 25 | $1.9B | $2.6B | ||
| Q4 24 | $1.9B | $2.7B | ||
| Q3 24 | $1.8B | $2.7B | ||
| Q2 24 | $1.8B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 4.40× | 0.13× | ||
| Q3 25 | 4.23× | — | ||
| Q2 25 | 4.14× | 0.18× | ||
| Q1 25 | 4.11× | 0.16× | ||
| Q4 24 | 4.12× | 0.14× | ||
| Q3 24 | 3.94× | 0.14× | ||
| Q2 24 | 3.98× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RM
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
